natgillin/translations-raw huggingface dataset:
Available data suggest that the clinical response is usually achieved within 14 weeks of treatment, i.e. three doses. 
Razpoložljivi podatki kažejo, da klinični odziv običajno dosežemo v 14 tednih zdravljenja, to je s tremi odmerki.
The median time to onset of response in the infliximab-treated group was 2 weeks. 
Mediani čas do nastopa odziva v skupini, zdravljeni z infliksimabom, je bil 2 tedna.
ACR-N uses the same criteria as the ACR20, calculated by taking the lowest percent improvement in swollen joint count, tender joint count, and the median of the remaining 5 components of the ACR response. 
ACR-N temelji na istih merilih kot ACR 20, kar se izračuna z upoštevanjem najmanjšega odstotnega izboljšanja števila oteklih sklepov, števila bolečih sklepov in mediane vrednosti preostalih 5 komponent odziva ACR.
This applies to both Crohn's disease patients and rheumatoid arthritis patients. 
To velja tako za bolnike s Crohnovo boleznijo kot za tiste z revmatoidnim artritisom.
Infliximab crosses the placenta and has been detected in the serum of infants up to 6 months following birth. 
Infliksimab prehaja skozi posteljico in so ga vse do 6 meseca po rojstvu zaznali v serumu dojenčkov.
In the infliximab group, the mean change in total modified vdH-S score remained below 0 at the week 54 timepoint. 
V skupini za prejemanje infliksimaba pa je ostala srednja vrednost spremembe skupnega modificiranega rezultata vdH-S pod vrednostjo 0 v časovni točki 54. tedna.
Three cases of pneumonia (1 serious) and 2 cases of herpes zoster (both non-serious) were reported. 
Poročali so tudi o treh primerih pljučnice (v enem primeru je šlo za resno pljučnico) in dveh primerih herpes zostra (noben od njiju ni bil resen).
This evaluation should include a detailed medical history with personal history of tuberculosis or possible previous contact with tuberculosis and previous and/or current immunosuppressive therapy. 
Pri tem morate opraviti podrobno zdravstveno anamnezo in osebno anamnezo v zvezi s tuberkulozo ali morebitnimi prejšnjimi stiki s tuberkuloznimi bolniki in v zvezi z morebitno prejšnjo in/ali sedanjo imunosupresivno terapijo.
Remicade should only be used in children if they are being treated for Crohn's disease or ulcerative colitis. 
Zdravilo Remicade se sme pri otrocih uporabljati samo za zdravljenje Crohnove bolezni ali ulceroznega kolitisa.
178 of the 580 enrolled patients (30.7%) were defined as having severe disease (CDAI score > 300 and concomitant corticosteroid and/or immunosuppressants) corresponding to the population defined in the indication (see section 4.1). 
Pri 178 od 580 v študijo vključenih bolnikov (30,7 %) so ugotovili hudo obliko bolezni (ocena CDAI > 300 in sočasna uporaba kortikosteroidov in /ali imunosupresivov), kar ustreza populaciji, opredeljeni v indikacijah (glejte poglavje 4.1).
What Remicade is and what it is used for What you need to know before you use Remicade How Remicade will be given Possible side effects 
Kaj je zdravilo Remicade in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo Remicade Kako uporabljati zdravilo Remicade Možni neželeni učinki
• Provision to record the type, date, and result of TB screenings 
• Prostor za beleženje tipa, datuma in rezultata presejalnih testov na TB.
In IMPACT and IMPACT 2, clinical responses were observed as early as week 2 and were maintained through week 98 and week 54 respectively. 
V študijah IMPACT in IMPACT 2 so opazili klinični odziv že v 2. tednu, ohranjen pa je bil tudi še v 98. tednu in 54. tednu.
What you need to know before you use Remicade 
Kaj morate vedeti, preden boste uporabili zdravilo Remicade
The antibody incidence was 2-3 fold higher for patients treated episodically. 
Pojavnost protiteles je bila 2 do 3-krat večja pri bolnikih, ki so bili zdravljeni občasno.
Improvement from baseline in HAQ averaged over time from week 30 to week 54 
Izboljšanje z začetne vrednosti za HAQ -časovno povprečje od 30. do 54. tedna
Clinical remission at week 8 was 33.3% (17/51) as measured by the Paediatric Ulcerative Colitis Activity Index (PUCAI) score. 
Klinična remisija v 8. tednu je bila 33,3 % (17/51) (merjeno z indeksom aktivnosti ulceroznega kolitisa pri pediatričnih bolnikih PUCAI [Paediatric Ulcerative Colitis Activity Index]).
Week-14 responders (195/282) were analysed for the primary endpoint, which was time from randomisation to loss of response (see Table 7). 
Pri bolnikih z odzivom v 14. tednu (195/282) so analizirali primarni končni rezultat, ki je bil čas od randomizacije do izginotja odziva (glejte Preglednico 7).
In all situations described below, the benefit/risk balance of Remicade therapy should be very carefully considered. 
V vseh spodaj opisanih okoliščinah, je treba zelo skrbno pretehtati razmerje med koristmi in tveganji zdravljenja z zdravilom Remicade.
One serious infusion reaction (< 1%) occurred in a patient on infliximab monotherapy. 
Pojavila se je ena resna z infuzijo povezana reakcija (< 1 %), in sicer pri bolniku na monoterapiji z infliksimabom.
• Feeling forgetful, irritable, confused, nervous 
• občutek pozabljivosti, razdražljivosti, zmedenosti, živčnosti
CDAI < 150 at both week 30 and 54 and not receiving corticosteroids in the 3 months prior to week 54 among patients who were receiving corticosteroids at baseline. 
CDAI < 150 tako v 30. tednu kot v 54. tednu, brez prejemanja kortikosteroidov v 3 mesecih pred 54. tednom pri bolnikih, ki so prejemali kortikosteroide na začetku študije
• You have tuberculosis (TB) or another serious infection such as pneumonia or sepsis. 
• če imate tuberkulozo (TBC) ali katero drugo hudo okužbo, npr. pljučnico ali sepso,
Patients with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections (see section 4.4). 
Bolniki s tuberkulozo ali z drugimi hudimi okužbami, kot so sepsa, abscesi in oportunistične okužbe (glejte poglavje 4.4).
Patients who responded at week 4 were followed to week 12. 
Bolnike z odzivom v 4. tednu so spremljali do 12. tedna.
If your baby has continual fevers or infections, contact your baby's doctor immediately. 
Če ima vaš dojenček pogosto zvišano telesno temperaturo ali okužbe, takoj obvestite njegovega zdravnika.
However, studies from the published literature in various indications (e.g. rheumatoid arthritis, psoriasis, Crohn's disease) suggest that non-live vaccinations received during treatment with anti-TNF therapies, including Remicade, may elicit a lower immune response than in patients not receiving anti-TNF therapy. 
Vseeno pa študije iz objavljene literature za različne indikacije (npr. revmatoidni artritis, psoriaza, Crohnova bolezen) nakazujejo, da cepljenja z neživimi cepivi med prejemanjem anti-TNF terapije, vključno z zdravilom Remicade, lahko izzovejo manjši imunski odgovor kot pri bolnikih, ki ne prejemajo anti-TNF terapije.
Results from week 54 (ACR20, total van der Heijde-modified Sharp score and HAQ) are shown in Table 3. 
Rezultati za 54. teden (za ACR 20, skupni rezultat po metodi van der Heijde, modificirani po Sharpu in HAQ) so prikazani v preglednici 3.
Approximately 93% of the patients had previously received antibiotic or immunosuppressive therapy. 
Približno 93 % teh bolnikov je pred tem prejemalo antibiotike ali zdravila za zaviranje imunske odzivnosti.
• Pain in the joints, muscles or back 
• bolečine v sklepih, mišicah ali hrbtu
Remicade must be given concomitantly with methotrexate. 
Zdravilo Remicade morate uporabljati sočasno z metotreksatom.
At baseline 27.4% of patients were receiving systemic corticosteroids, 14.2% of patients were receiving budesonide, and 54.3% of patients were receiving 5-ASA compounds. 
Na začetku študije je 27,4 % bolnikov prejemalo sistemske kortikosteroide, 14,2 % bolnikov je prejemalo budezonid in 54,3 % bolnikov je prejemalo spojine 5-ASA.
• Children and adults taking Remicade may have an increased risk of developing lymphoma or another cancer. 
• Otroci in odrasli, ki prejemajo zdravilo Remicade, imajo lahko povečano tveganje za pojav limfoma ali katere druge vrste raka.
If you received Remicade while pregnant, giving BCG vaccine (used to prevent tuberculosis) to your baby within 6 months after birth may result in infection with serious complications, including death. 
Če ste v času nosečnosti prejeli zdravilo Remicade, lahko cepljenje dojenčka s cepivom BCG (uporablja se za preprečevanje tuberkuloze) v obdobju 6 mesecev po rojstvu povzroči okužbo z resnimi zapleti, vključno s smrtjo.
The storage details should you need them are as follows: 
Pogoji shranjevanja so naslednji:
At baseline, 87% of the patients had perianal fistulae, 14% had abdominal fistulae, 9% had rectovaginal fistulae. 
Na začetku je 87 % bolnikov imelo perianalne fistule, 14 % jih je imelo abdominalne fistule in 9 % rektovaginalne fistule.
• Talk to you doctor if you have recently received or are scheduled to receive treatment with a therapeutic infectious agent (such as BCG instillation used for the treatment of cancer). 
• Obvestite zdravnika, če ste pred kratkim prejeli ali boste prejeli povzročitelje okužb v terapevtske namene (kot je uporaba BCG za zdravljenje raka).
Table 6 Percent of patients achieving corticosteroid-free clinical remission at week 26, SONIC 
Preglednica 6 Odstotek bolnikov, ki so dosegli klinično remisijo brez jemanja kortikosteroidov v 26. tednu, SONIC
• Some patients receiving Remicade have developed symptoms of an immune system disorder called lupus. 
• Pri nekaterih bolnikih, ki prejemajo zdravilo Remicade, so se pojavili simptomi bolezni imunskega sistema, imenovane lupus.
Low blood counts 
Nizko število krvnih celic
There was no significant difference between placebo and infliximab for the proportion of patients with sustained closure of all fistulas through week 54, for symptoms such as proctalgia, abscesses and urinary tract infection or for number of newly developed fistulas during treatment. 
Ni bilo bistvene razlike med placebom in infliksimabom v odstotku bolnikov z ohranjenim zaprtjem vseh fistul do 54. tedna, za simptome, kot so proktalgija, abscesi in okužba sečil ali za število med zdravljenjem novonastalih fistul.
Emergency equipment, such as adrenaline, antihistamines, corticosteroids and an artificial airway must be available. 
Na voljo morajo biti sredstva za nujno pomoč, npr. adrenalin, antihistaminiki, kortikosteroidi in oprema za umetno ventilacijo.
Ulcerative colitis (6 to 17 years) 
Ulcerozni kolitis (od 6 do 17 let)
Remicade may have a minor influence on the ability to drive and use machines. 
Zdravilo Remicade ima lahko blag vpliv na sposobnost vožnje in upravljanja strojev.
Your doctor will record these tests on your patient reminder card. 
Zdravnik bo vpisal te preiskave na vašo opozorilno kartico za bolnika.
The majority of serious infusion reactions occurred during the second infusion at week 2. 
Večina resnih z infuzijo povezanih reakcij se je pojavila v času, ko so prejemali drugo infuzijo zdravila v 2. tednu zdravljenja.
Insert the syringe needle into the vial through the centre of the rubber stopper and direct the stream of water for injections to the glass wall of the vial. 
Zabodite iglo skozi osrednji del gumijastega zamaška viale in usmerite curek vode za injekcije proti stekleni steni viale.
The proportion of subjects who underwent colectomy at any time within 54 weeks following the first infusion of study agent were collected and pooled from the ACT 1 and ACT 2 studies and their extensions. 
Podatke o odstotku preiskovancev, ki so jim opravili kolektomijo kadarkoli v času 54 tednov po prvi infuziji proučevanega zdravila iz študij ACT 1 in ACT 2 ter njihovih podaljšanj, so zbrali in jih združili.
Psoriatic arthritis is an inflammatory disease of the joints, usually accompanied by psoriasis. 
Psoriatični artritis je vnetna bolezen sklepov, ki jo običajno spremlja psoriaza.
At single doses of 3, 5, or 10 mg/kg, the median Cmax values were 77, 118 and 277 micrograms/ml, respectively. 
Po enkratnem odmerku 3, 5 ali 10 mg/kg so bile mediane vrednosti Cmaks 77, 118 in 277 mikrogramov/ml.
However, the results are uncertain due to limitations in the methods used for serum analyses of infliximab and antibodies against infliximab. 
Ti izsledki pa so nezanesljivi zaradi pomanjkljivosti metod, uporabljenih za serumske analize infliksimaba in protiteles proti njemu.
In the REACH study, infections were reported in 56.3% of randomised subjects treated with infliximab. 
V preskušanju REACH so o okužbah poročali pri 56,3 % randomiziranih preiskovancih, zdravljenih z infliksimabom.
If these medicines or treatments do not work well enough, you will be given Remicade to reduce the signs and symptoms of your disease. 
Če ta zdravila ali terapije ne delujejo dovolj dobro, boste prejeli zdravilo Remicade za zmanjševanje znakov in simptomov bolezni.
Studies in mice deficient in TNF demonstrated no increase in tumours when challenged with known tumour initiators and/or promoters. 
Študije pri miših s pomanjkanjem TNF niso pokazale povečanja pogostnosti tumorjev po provokaciji z znanimi sprožilci novih tumorjev in/ali spodbujevalci.
Every 6 to 8 weeks depending on your disease 
6 tednov po prvem odmerku nadaljnji odmerki vsakih 6 do 8 tednov, odvisno od vaše bolezni
The relative deficiency of TNF caused by anti-TNF therapy may result in the initiation of an autoimmune process. 
Relativno pomanjkanje TNF kot posledica anti-TNF terapije lahko sproži avtoimunski proces.
Discard this medicine if not used by the new expiry date or the expiry date printed on the carton, whichever is earlier. 
To zdravilo zavrzite, če ga ne uporabite do izteka novega roka uporabnosti ali roka uporabnosti, natisnjenega na škatli, kar nastopi prej.
Thereafter, all subjects continued on infliximab every 6 weeks to week 96. 
Potem so vsi preiskovanci nadaljevali z jemanjem infliksimaba na vsakih 6 tednov, do 96. tedna.
List of allergies: 
Alergije:
• Serious skin problems such as toxic epidermal necrolysis, Stevens-Johnson Syndrome and acute generalised exanthematous pustulosis 
• resne težave s kožo, na primer toksična epidermalna nekroliza, Stevens-Johnsonov sindrom in akutna generalizirana eksantematozna pustuloza
These skin reactions can be accompanied by fever. 
Te kožne reakcije lahko spremlja zvišana telesna temperatura.
Current data do not indicate that infliximab treatment influences the risk for developing dysplasia or colon cancer. 
Dosedanji podatki ne kažejo, da zdravljenje z infliksimabom vpliva na tveganje za nastanek displazije ali karcinoma kolona.
Invasive fungal infections may present as disseminated rather than localised disease, and antigen and antibody testing may be negative in some patients with active infection. 
Invazivne glivične okužbe lahko namesto v obliki lokalizirane nastopajo v obliki diseminirane bolezni, poleg tega pa sta lahko pri nekaterih bolnikih z aktivno okužbo testa na antigen in protitelesa negativna.
≥ 90% improvement ≥ 75% improvement ≥ 50% improvement 
≥ 90 % izboljšanje ≥ 75 % izboljšanje ≥ 50 % izboljšanje
At the last evaluation, 57% of infliximab-treated patients remained anti-dsDNA positive. 
Ob zadnji oceni je bilo 57 % bolnikov, zdravljenih z infliksimabom, še vedno pozitivnih na anti-dsDNA.
Sustained response (clinical response at both week 8 and week 30) 
Trajnejši odziv (klinični odziv tako v 8. tednu kot v 30. tednu)
If you have moderate to severe plaque psoriasis, you will first be given other medicines or treatments, such as phototherapy. 
Če imate zmerno do hudo psoriazo s plaki, boste najprej prejeli druga zdravila ali drugo terapijo, npr. fototerapijo.
• New or worsening heart failure, slow heart rate 
• novo nastalo srčno popuščanje ali poslabšanje srčnega popuščanja, počasen srčni utrip
• Tell your doctor straight away if you have signs of an infection. 
• Zdravniku morate takoj povedati, če imate znake, ki kažejo na okužbo.
• Worsening of a condition called dermatomyositis (seen as a skin rash accompanying muscle weakness) 
• poslabšanje dermatomiozitisa (ki se kaže kot kožni izpuščaj, ki spremlja šibkost mišic)
• Serious lung problems (such as interstitial lung disease) 
• resne težave s pljuči (na primer intersticijska pljučna bolezen)
Administration of Remicade should be discontinued if a patient develops a new serious infection or sepsis, and appropriate antimicrobial or antifungal therapy should be initiated until the infection is controlled. 
Uporabo zdravila Remicade prekinite, če se pri bolniku pojavi nova resna okužba ali sepsa, in mu uvedite ustrezno protimikrobno ali protiglivično terapijo, dokler ne bo okužba obvladana.
Reconstitute and dilute before use. 
Pred uporabo rekonstituirajte in razredčite.
• Tell your surgeon or dentist that you are having treatment with Remicade by showing them your patient reminder card. 
• Obvestite kirurga ali zobozdravnika, da prejemate zdravilo Remicade in mu pokažite svojo opozorilno kartico za bolnika.
• Some children and teenage patients who have received TNF-blockers such as Remicade have developed cancers, including unusual types, which sometimes resulted in death. 
• Pri nekaterih otrocih in najstnikih, ki so prejemali zaviralce TNF, kot je zdravilo Remicade, se je razvil rak, vključno z zelo neobičajnimi oblikami, ki se včasih končajo s smrtnim izidom.
Infliximab is a monoclonal antibody - a type of protein that attaches to a specific target in the body called TNF (tumour necrosis factor) alpha. 
Infliksimab je monoklonsko protitelo - vrsta beljakovine, ki se veže na določeno tarčo v telesu, imenovano TNF (tumorje nekrotizirajoči faktor) alfa.
Dosing continued for all patients through week 46. 
Odmerjanje zdravila se je potem nadaljevalo do 46. tedna za vse bolnike.
In a 1-year clinical study with repeated infusions in patients with Crohn's disease (ACCENT I study), the incidence of serum sickness-like reactions was 2.4%. 
V enoletni študiji z večkratnimi infuzijami zdravila pri bolnikih s Crohnovo boleznijo (študija ACCENT I), je bila incidenca reakcij, podobnih serumski bolezni, 2,4 %.
Other medicines and Remicade 
Druga zdravila in zdravilo Remicade
Placebo (week 16) 
Placebo (16. teden)
Tell your doctor if you are using or have recently used any other medicines, including any other medicines to treat Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or psoriasis or medicines obtained without a prescription, such as vitamins and herbal medicines. 
Obvestite zdravnika, če jemljete ali ste pred kratkim jemali katero koli zdravilo, vključno s katerimi koli drugimi zdravili za zdravljenje Crohnove bolezni, ulceroznega kolitisa, revmatoidnega artritisa, ankilozirajočega spondilitisa, psoriatičnega artritisa ali psoriaze in z zdravili, ki se jih dobi brez recepta, kot so vitamini in rastlinski pripravki.
• Tell your doctor before you are given Remicade if you have ever lived in or travelled to an area where infections called histoplasmosis, coccidioidomycosis, or blastomycosis are common. 
• Preden prejmete zdravilo Remicade, povejte zdravniku, če ste kdaj živeli v ali potovali po krajih, kjer so pogoste okužbe, imenovane histoplazmoza, kokcidioidomikoza ali blastomikoza.
Currently available pharmacokinetic data are described in section 5.2 but no recommendation on a posology can be made in children younger than 6 years. 
Trenutno razpoložljivi farmakokinetični podatki so opisani v poglavju 5.2, vendar ni mogoče podati priporočil za odmerjanje za otroke, mlajše od 6 let.
In order to improve the traceability of biological medicinal products, the tradename and batch number of the administered medicinal product should be clearly recorded. 
Zaradi izboljšanja sledljivosti bioloških zdravil morata biti jasno zabeležena lastniško ime in številka serije uporabljenega zdravila.
• Abnormal tissue swelling or growth 
• nenormalno otekanje ali rast tkiva
• Collections of immune cells resulting from an inflammatory response (granulomatous lesions) 
• kopičenje imunskih celic zaradi vnetnega odziva (granulomatozne lezije)
Women of childbearing potential should consider the use of adequate contraception to prevent pregnancy and continue its use for at least 6 months after the last Remicade treatment. 
Ženske v rodni dobi morajo za preprečevanje nosečnosti razmisliti o uporabi ustrezne kontracepcije in z njo nadaljevati še najmanj 6 mesecev po zaključku zdravljenja z zdravilom Remicade.
In general, patients who developed ALT and AST elevations were asymptomatic, and the abnormalities decreased or resolved with either continuation or discontinuation of Remicade, or modification of concomitant therapy. 
Na splošno bolniki, pri katerih se je pojavilo zvišanje ALT in AST, niso imeli simptomov in nenormalni izvidi so se zmanjšali ali normalizirali bodisi z nadaljevanjem ali z ukinitvijo zdravljenja z zdravilom Remicade, ali pa ob prilagoditvi drugih sočasnih terapij.
A reduction in signs and symptoms was defined to be at least a 20% improvement (ACR20) in both tender and swollen joint counts, and in 3 of the following 5 criteria: (1) evaluator's global assessment, (2) patient's global assessment, (3) functional/disability measure, (4) visual analogue pain scale and (5) erythrocyte sedimentation rate or C-reactive protein. 
Zmanjšanje znakov in simptomov so opredelili kot najmanj 20 % izboljšanje (ACR 20) števila bolečih in oteklih sklepov ter 3 od naslednjih 5 meril: (1) zdravnikove splošne ocene, (2) bolnikove splošne ocene, (3) merila funkcionalne prizadetosti/neprizadetosti, (4) vizualne analogne lestvice bolečine in (5) hitrosti sedimentacije eritrocitov ali C-reaktivnega proteina.
• Liver problem that causes yellowing of the skin or eyes (jaundice) 
• težave z jetri, ki povzročajo porumenelost kože ali oči (zlatenica)
Janssen Biologics B.V., Einsteinweg 101, 2333 CB Leiden, The Netherlands 
Janssen Biologics B.V., Einsteinweg 101 2333 CB Leiden, Nizozemska
• Swelling of small blood vessels (vasculitis) 
• otekanje majhnih krvnih žil (vaskulitis)
• Temporary loss of sight during or within 2 hours of infusion 
• začasna izguba vida med infundiranjem ali v roku 2 ur po infundiranju
The effect of concomitant immunomodulator therapy was more profound in episodically-treated patients than in patients given maintenance therapy. 
Učinek sočasne terapije z imunomodulatorji je bil močnejši pri občasno zdravljenih bolnikih kot pri tistih na vzdrževalni terapiji.
• Your doctor will also give you a patient reminder card, which contains important safety information you need to be aware of before and during your treatment with Remicade. 
• Zdravnik vam bo dal tudi opozorilno kartico za bolnika, na kateri so navedeni pomembnejši varnostni podatki, ki jih morate poznati, preden prejmete zdravilo Remicade in tudi med zdravljenjem z njim.
Instructions for use and handling - reconstitution, dilution and administration 
Navodila za uporabo in ravnanje z zdravilom - rekonstitucija, redčenje in infundiranje
This patient reminder card contains important safety information that you need to be aware of before and during treatment with Remicade. 
Ta opozorilna kartica za bolnika vsebuje pomembne varnostne informacije, ki jih morate poznati preden prejmete zdravilo Remicade ter med zdravljenjem z njim.
• Viral infections such as herpes or flu 
• virusne okužbe, na primer herpes ali gripa
You may receive some vaccines during treatment with Remicade but you should not receive live vaccines (vaccines that contain a living but weakened infectious agent) while using Remicade because they may cause infections. 
Med zdravljenjem z zdravilom Remicade lahko prejmete nekatera cepiva, vendar med uporabo zdravila Remicade ne smete prejeti živih cepiv (cepiv, ki vsebujejo žive, a oslabljene povzročitelje okužb), saj lahko le-ta povzročijo okužbo.
A response was observed within 2 weeks, with a maximum response at 4 weeks. 
Klinični odziv na zdravljenje so ugotavljali v roku 2 tednov, največji odziv pa po 4 tednih.
A total of 573 patients with moderately to severely active Crohn's disease (CDAI ≥ 220 ≤ 400) received a single infusion of 5 mg/kg at week 0. 
Skupaj 573 bolnikov z zmerno do hudo aktivno Crohnovo boleznijo (CDAI ≥ 220 ≤ 400) je prejelo enkratno infuzijo odmerka 5 mg/kg v tednu 0.
Remicade should be administered intravenously over a 2 hour period. 
Zdravilo Remicade je treba dajati intravensko v času 2 ur.